What is the appropriate intravenous immunoglobulin (IVIG) dosing regimen for a 50‑kg patient experiencing myasthenia gravis crisis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

IVIG Dosing for Myasthenia Gravis Crisis

For a 50-kg patient in myasthenic crisis, administer IVIG at 0.4 g/kg/day for 5 consecutive days, which equals 20 grams per day for a total dose of 100 grams (2 g/kg total). 1

Standard Dosing Protocol

The established dose for myasthenic crisis is 2 g/kg total body weight administered over 5 days. 1, 2 For your 50-kg patient, this translates to:

  • Daily dose: 20 grams (0.4 g/kg/day)
  • Total dose: 100 grams over 5 consecutive days
  • Infusion rate: Start at 0.01 mL/kg/min (0.5 mg/kg/min), increase gradually to maximum 0.10 mL/kg/min (5 mg/kg/min) if tolerated 3

Evidence Base and Clinical Context

The 2 g/kg total dose represents the standard of care supported by multiple high-quality randomized controlled trials. 2, 4 A 2007 level 1 evidence study demonstrated clinically meaningful improvement at day 14 that persisted through day 28, with greatest benefit in patients with more severe disease (QMG score >10.5). 2

A 2005 multicenter randomized trial directly compared 1 g/kg versus 2 g/kg dosing and found no significant superiority of the higher dose (mean improvement 15.49 points vs 19.33 points, p=0.12). 4 However, the 2 g/kg regimen remains standard practice because the numerical trend favored higher dosing and the study may have been underpowered. 4

Critical Management Considerations

Infusion Administration

  • Begin infusion slowly at 0.01 mL/kg/min for the first 30 minutes, monitoring vital signs continuously 3
  • Gradually increase to maximum 0.10 mL/kg/min if well-tolerated 3
  • Slow or stop if adverse reactions occur; resume at lower rate once symptoms subside 3

Pre-Treatment Assessment

Check serum IgA levels before first infusion because IgA deficiency increases anaphylaxis risk; use IVIG preparations with reduced IgA content if deficiency confirmed. 5, 3 Patients with anti-IgA antibodies and history of hypersensitivity reactions are at highest risk for severe reactions. 3

Concurrent Crisis Management

  • Continue pyridostigmine during IVIG unless intubation required 1
  • Maintain or initiate corticosteroids concurrently (prednisone 1-1.5 mg/kg/day) 1
  • Monitor respiratory function frequently with negative inspiratory force and vital capacity measurements 1, 5
  • ICU-level monitoring is mandatory for Grade 3-4 myasthenic crisis 1

Medications to Strictly Avoid

Immediately discontinue and avoid β-blockers, IV magnesium, fluoroquinolone antibiotics, aminoglycoside antibiotics, and macrolide antibiotics, as these worsen neuromuscular transmission and can precipitate further deterioration. 1

Alternative Considerations

Plasmapheresis is equally effective as IVIG for myasthenic crisis and may be preferred if IVIG is contraindicated, though it requires specialized equipment and has higher rates of severe complications. 6 A 2024 meta-analysis showed plasmapheresis offered superior short-term symptom improvement but IVIG resulted in shorter hospital stays and lower complication rates. 6

Sequential therapy (plasmapheresis followed by IVIG) provides no additional benefit over either treatment alone and should be avoided. 1

Monitoring During Treatment

  • Renal function: Monitor BUN and creatinine before infusion and at appropriate intervals, especially in patients >65 years, with pre-existing renal insufficiency, diabetes, volume depletion, or receiving nephrotoxic drugs 3
  • Hematologic: Monitor for hemolysis, particularly with high doses and non-O blood groups 3
  • Neurologic: Daily assessments of muscle strength, bulbar function, and respiratory status 1

Common Pitfalls

Do not use IVIG for chronic maintenance therapy in myasthenia gravis—it is indicated only for acute exacerbations or crisis situations. 1 A 2025 trial of maintenance IVIG (1 g/kg every 3 weeks) showed no significant benefit on primary endpoints. 7

Do not dose based on ideal body weight—use actual body weight for IVIG dosing in myasthenia gravis crisis, as the standard 2 g/kg protocol is based on total body weight. 1, 2, 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.